{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-109105","form_type":"8-K","ticker":null,"cik":"0001739426","company_name":"RVL Pharmaceuticals plc","filed_at":"2023-10-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.271299+00:00","generated_at":"2026-06-10T00:06:11.968765+00:00","sec_items":["1.03","2.03","3.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"RVL Pharmaceuticals subsidiaries file Chapter 11; parent to wind down; equity expected worthless","bullets":["Three indirect subsidiaries filed voluntary Chapter 11 on Oct 12, 2023; parent RVL PLC not in bankruptcy but plans wind-down.","Prepackaged plan: Athyrium Capital Management to exchange debt for 97.5% of NewCo equity; SPA rejection claims get 2.5%.","DIP financing of up to $17.5M from Athyrium, with $7.5M available upon interim order approval; minimum liquidity $2.5M.","Nasdaq delisting notice received Oct 12; trading suspended Oct 23, 2023; no appeal planned.","All RVL PLC ordinary shares expected to be cancelled upon wind-down completion by end of 2024, likely no recovery."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-109105","json":"https://secwatch.observer/filing/0001104659-23-109105.json","markdown":"https://secwatch.observer/filing/0001104659-23-109105.md","text":"https://secwatch.observer/filing/0001104659-23-109105.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739426/000110465923109105/0001104659-23-109105-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739426/000110465923109105/tm2328340d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T00:06:11.968765+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c7b90dff436147e589e311441503c879e085a08a","claim":"RVL Pharmaceuticals plc entered chapter 11 in United States Bankruptcy Court for the District of Delaware (petition 2023-10-12).","evidence_excerpt":"filed voluntary petitions (Case No. 23-11704 (BLS)) (the “Chapter 11 Cases”) for relief under Chapter 11 of title 11 of the United States Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”).","evidence_source":"SEC 8-K Item 1.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1739426/000110465923109105/0001104659-23-109105-index.htm","confidence":0.9,"family_label":"Distress & Bankruptcy","details":[{"label":"Proceeding","value":"chapter 11"},{"label":"Court","value":"United States Bankruptcy Court for the District of Delaware"},{"label":"Petition","value":"2023-10-12"}],"fact_type":"distress_event"},{"claim_id":"80c1648ebc58c231b5913d71f9f7c47b3cc7b075","claim":"RVL Pharmaceuticals plc received a nasdaq delisting notice notice regarding other (rules 5101, 5110(b), IM-5101-1).","evidence_excerpt":"October 12, 2023, RVL PLC received written notice (the “Delisting Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) notifying RVL PLC that, as a result of the Chapter 11 Cases and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, Nasdaq had determined that RVL PLC’s Ordinary Shares will be delisted from Nasdaq. RVL PLC does not intend to appeal this determination. Trading of RVL PLC’s Ordinary Shares will be suspended at the opening of business on October 23, 2023, and Nasdaq will file a Form 25-NSE with the Securities and Exchange","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1739426/000110465923109105/0001104659-23-109105-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"delisting notice"},{"label":"Rules","value":"5101, 5110(b), IM-5101-1"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}